CRYSTALLINE H-MODIFICATION OF 2-AMINO-2-(2-(4-OCTYLPHENYL) ETHYL)PROPANE-1,3-DIOLE HYDROCHLORIDE, METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON Russian patent published in 2017 - IPC C07C215/36 C07C213/10 A61P37/06 A61P9/10 

Abstract RU 2627691 C1

FIELD: pharmacology.

SUBSTANCE: invention relates to a new crystalline ηmodification of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride (fingolimod hydrochloride), its preparation method and application. This crystalline ηmodification can be used to prepare a pharmaceutical composition as an immunosuppressant for treatment of relapsing-remitting multiple sclerosis. Crystalline ηmodification of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride is characterized by the following set of interplanar distances (d, E) and their corresponding intensities (Irel., %) 25.199 - 100.00%; 12.569 - 4.46%; 8.362 - 8.20%; 7.171 - 3.10%; 6.705 - 1.11%; 5.841 - 5.94%; 4.985 - 2.63%; 4.572 - 4.96%; 4.341 - 9.98%; 4.176 - 8.11%; 4.073 - 4.77%; 3.867 - 4.27%; 3.776 - 2.14%; 3.581 - 3.02%; 3.393 - 3.34%; 3.185 - 1.07%; 3.069 - 2.65%; 3.005 - 1.17%; 2.991 - 1.13%; 2.842 - 1.25%; 2.802 - 1.56%, as well as by a set of endothermic effects on the DSC curve at temperatures (40.7±0.5)°C; (107.6±0.5)°C; (261.5±0.5)°C. A method for production of a crystalline ηmodification of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride includes freezing of an aqueous solution of fingolimod hydrochloride with a concentration of 0.5-8.0 wt %, at 25-100°C, acidified with hydrochloric acid to pH=(5-2), at a cooling rate of at least 60 deg/min and freeze dried. It is desirable to freeze dry the frozen solution of fingolimod hydrochloride at the following temperatures: (-43…-75)°C on the condenser; (-196…+50)°C on the product, and the residual pressure of (9-3)×10-2 Torr in the chamber, for 22-26 hours.

EFFECT: method allows to obtain a pure stable crystalline modification, which is a powder of white or almost white colour, odorless, water soluble, readily soluble in low molecular weight alcohols, dimethylsulfoxide, practically insoluble in acetonitrile.

4 cl, 6 dwg, 4 tbl, 4 ex

Similar patents RU2627691C1

Title Year Author Number
CRYSTALLINE β-MODIFICATION OF N-(3-ETHYLPHENYL)-6,7-BIS(2 METHOXYETHOXY)QUINAZOLINE-4-AMINE HYDROCHLORIDE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON 2015
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2610337C1
CRYSTALLINE β-MODIFICATION OF 3-(4-AMINO-1-OXO-1,3-DIHYDRO-2H-ISOINDOL-2-YL)-PIPERIDINE-2,6-DIONE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON 2016
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2616976C1
CRYSTALLINE γ-MODIFICATION OF N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINOLINE AMINE OF BIS (4-METHYLBENZENESULFONATE) MONOHYDRATE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON 2016
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2603943C1
CRYSTAL ANHYDROUS DELTA MODIFICATION OF N-(2-CHLORINE-6-METHYLPHENYLDIAZOMETHANE)-2-[6-[4-(2-HYDROXYETHYL)-1-PIPERAZINYL]-2-METHYL-4-PIRIMIDINYL]AMINO]-5-THIAZOLCARBOXAMIDE, METHOD OF ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED ON IT 2014
  • Malin Aleksandr Aleksandrovich
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
RU2567537C1
NANOSIZE WEAKLY CRYSTALLINE MODIFICATION OF 4-METHYL-N-[3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL]-3-[(4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO]BENAZAMIDE HYDROCHLORIDE MONOHYDRATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON 2013
  • Malin Aleksandr Aleksandrovich
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
RU2551359C1
CRYSTALLINE B-MODIFICATION OF BENZYLDIMETHYL[3- (MYRISTOYLAMINO)PROPYL]AMMONIUM OF MONOHYDRATE CHLORIDE, METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION BASED THEREON 2016
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2626877C1
CRYSTAL BETA-MODIFICATION OF (E)-DIMETHYL BUTENEDIOATE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION ON ITS BASIS 2016
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2616605C1
WEAKLY CRYSTALLISED β-MODIFICATION OF (S)-ISOPROPYL 2-((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)-(PHENOXY)PHOSPHORYLAMINO)PROPANOATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON 2017
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2656228C9
CRYSTALLINE ε-MODIFICATION OF N-[2-(DIETHYLAMINO)ETHYL]-5-[(Z)-(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDENE)METHYL]-2,4-DIMETHYL-1H-PYRROL-3-CARBOXAMIDE MALATE, METHOD FOR PRODUCING SAME AND BASED PHARMACEUTICAL COMPOSITION 2014
  • Malin Aleksandr Aleksandrovich
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
RU2567535C1
CRYSTALLINE β-MODIFICATION OF 4-[4-({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]CARBAMOYL}AMINO)PHENOXY]-N-METHYL-PYRIDINE-2-CARBOXAMIDE OF p-TOLUENE SULPHONATE, METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION BASED THEREON 2015
  • Mikhajlov Oleg Rostislavovich
  • Uvarov Nikolaj Aleksandrovich
  • Malin Aleksandr Aleksandrovich
RU2568638C1

RU 2 627 691 C1

Authors

Mikhajlov Oleg Rostislavovich

Uvarov Nikolaj Aleksandrovich

Malin Aleksandr Aleksandrovich

Dates

2017-08-10Published

2016-07-06Filed